MarketCapExport financials
Viemed Healthcare (VMD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Viemed Healthcare Income Statement 2025-2011 | VMD
Brief overview of financial results at Viemed Healthcare
The conclusions below are based on five years of reported results. Viemed Healthcare reported revenue of 131 million dollars in 2020 and 270 million dollars by 2025. Overall revenue changed by +105.8%, equal to an annualized rate of about 15.5%. The company expanded its sales base at a healthy rate.
At the gross-profit level, the result moved from $80.1 million to $155 million, a change of +94.1%. The relationship between sales and direct costs deteriorated. Comparing the endpoints gives gross margins of 61% and 57.5%. A lower margin indicates deterioration in the economics of the core business.
EBITDA was 25.3 million dollars at the beginning and 51.6 million dollars at the end of the period (+104.1%). Operating performance was consistent with the change in sales. The EBITDA share of revenue changed from 19.2% to 19.1%. EBITDA as a share of revenue remained steady.
Net profit was $31.5 million at the start and $14.9 million at the end. Profit pressure may reflect higher operating, financing, or tax costs.
Market capitalization changed from 328 million dollars to 352 million dollars (+7.4%). Capitalization moved ahead of the business fundamentals.
What the figures show
Positive developments coexist with areas of weakness. The financial profile benefits from sales growth and a steady EBITDA margin. The main areas of concern are weaker gross profitability and lower net income. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Viemed Healthcare
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
352 M | 351 M | 357 M | 352 M | 183 M | 328 M | 206 M | - | - | - | - | - | - | - | - |
Shares |
38.9 M | 38.8 M | 38.4 M | 38.7 M | 39.5 M | 39.1 M | 37.7 M | - | - | - | - | - | - | - | - |
Historical Prices |
9.06 | 9.06 | 9.32 | 9.1 | 4.63 | 8.39 | 5.25 | - | - | - | - | - | - | - | - |
Net Income |
15.4 M | 11.4 M | 10.2 M | 6.2 M | 9.13 M | 31.5 M | 8.52 M | 10.2 M | 8.18 M | 1.23 M | - | - | - | - | - |
Revenue |
270 M | 224 M | 183 M | 139 M | 117 M | 131 M | 80.3 M | 65.3 M | 46.9 M | 31.4 M | - | - | - | - | - |
Cost of Revenue |
115 M | 91.1 M | 70.2 M | 54.2 M | 43.7 M | 51.2 M | 24.2 M | 16.7 M | - | - | - | - | - | - | - |
Gross Profit |
155 M | 133 M | 113 M | 84.7 M | 73.4 M | 80.1 M | 56 M | 48.6 M | 34.6 M | 18.9 M | - | - | - | - | - |
Operating Income |
22.9 M | 17.9 M | 14.3 M | 8.25 M | 11.6 M | 26.8 M | 8.86 M | 10.1 M | - | - | - | - | - | - | - |
Interest Expense |
252 K | -173 K | 98 K | 989 K | 1.62 M | 3.95 M | -3 K | - | - | - | - | - | - | - | - |
EBITDA |
51.6 M | 43.3 M | 36.2 M | 23.9 M | 22.9 M | 25.3 M | 9.89 M | 17.6 M | 14.4 M | 5.09 M | - | - | - | - | - |
Operating Expenses |
133 M | 115 M | 98.5 M | 76.4 M | 61.8 M | 55.7 M | 46.8 M | 31.5 M | 20.6 M | 14.1 M | - | - | - | - | - |
General and Administrative Expenses |
121 M | 106 M | 87.9 M | 68.2 M | 54.9 M | 57.7 M | 45.3 M | 30.7 M | 20.2 M | 13.8 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Viemed Healthcare
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
38.1 M | 38.2 M | 38.4 M | -295 K | 38.6 M | 39.5 M | 39.4 M | -49 K | 38.9 M | 38.8 M | 38.7 M | 46.7 M | 38.4 M | 38.3 M | 38.2 M | -216 K | 38.2 M | 38.8 M | 39.6 M | 49 M | 39.6 M | 39.6 M | 39.1 M | 39.2 M | 39.1 M | 38.7 M | 38 M | 38 M | 37.8 M | 37.7 M | 37.8 M | 37.5 M | 37.9 M | 37.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
4.74 M | 2.9 M | 2.71 M | 5.82 M | 3.6 M | 3.25 M | 2.71 M | 4.42 M | 3.9 M | 1.48 M | 1.6 M | 3.48 M | 2.92 M | 2.33 M | 1.52 M | 2.44 M | 1.06 M | 967 K | 1.76 M | 4.09 M | 1.79 M | 1.57 M | 1.68 M | 5.07 M | 2.8 M | 19.4 M | 4.24 M | 2.39 M | 2.85 M | 1.33 M | 1.96 M | 2.97 M | 2.22 M | 2.1 M | 2.22 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
80.7 M | 78.1 M | 75.4 M | 76.2 M | 71.9 M | 63.1 M | 59.1 M | 60.7 M | 58 M | 55 M | 50.6 M | 50.7 M | 49.4 M | 43.3 M | 39.6 M | 37.5 M | 35.8 M | 33.3 M | 32.3 M | 32 M | 29.3 M | 27.4 M | 28.4 M | 31.2 M | 33.4 M | 42.9 M | 23.8 M | 21.4 M | 20.4 M | 20.3 M | 18.1 M | 18.4 M | 16.9 M | 15.2 M | 14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
34.5 M | 33 M | 32.6 M | 32.1 M | 30.6 M | 26.3 M | 25.8 M | 24.6 M | 23.6 M | 22.1 M | 20.8 M | 18.6 M | 18.8 M | 17.2 M | 15.6 M | 14.6 M | 14.1 M | 12.9 M | 12.5 M | 12.3 M | 10.9 M | 9.77 M | 10.7 M | 12 M | 14 M | 16.9 M | 8.25 M | 7.2 M | 6.32 M | 5.69 M | 5.04 M | 4.84 M | 4.1 M | 4.18 M | 3.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
46.2 M | 45 M | 42.8 M | 44.1 M | 41.3 M | 36.7 M | 33.3 M | 36.1 M | 34.4 M | 32.9 M | 29.8 M | 32.1 M | 30.6 M | 26.1 M | 24 M | 22.9 M | 21.7 M | 20.4 M | 19.7 M | 19.7 M | 18.4 M | 17.6 M | 17.7 M | 19.2 M | 19.5 M | 25.9 M | 15.6 M | 14.2 M | 14 M | 14.6 M | 13.1 M | 13.5 M | 12.8 M | 11 M | 10.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
6.96 M | 4.46 M | 4.3 M | 8.37 M | 5.64 M | 5.1 M | 3.84 M | 6.45 M | 5.63 M | 3.62 M | 2.2 M | 5.29 M | 4.21 M | 2.9 M | 1.93 M | 3.53 M | 1.47 M | 1 M | 2.25 M | 4.66 M | 2.92 M | 2.66 M | 1.33 M | 5.27 M | 4.04 M | 12.9 M | 4.62 M | 2.69 M | 2.19 M | 1.66 M | 2.32 M | 2.92 M | 2.51 M | 2.29 M | 2.34 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
59 K | 67 K | 35 K | 61 K | 44 K | 72 K | 75 K | 88 K | 276 K | -563 K | 26 K | -26 K | 41 K | 2 K | 81 K | 268 K | 57 K | 223 K | 441 K | 1.54 M | 32 K | 32 K | -55 K | 359 K | 19 K | 3.57 M | - | -4 K | -1 K | 1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
7.35 M | 4.85 M | 4.68 M | 7.47 M | 6.04 M | 5.45 M | 4.19 M | 5.41 M | 5.98 M | 3.99 M | 2.62 M | -90 K | 4.62 M | 3.2 M | 6.7 M | 7.91 M | 5.59 M | 4.74 M | 5.64 M | 7.78 M | 5.79 M | 5.38 M | 3.94 M | 8.1 M | 6.46 M | 15 M | 6.74 M | 4.69 M | 3.84 M | 4.4 M | 3.72 M | 2.92 M | 5.12 M | 3.92 M | 2.34 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
39.2 M | 40.6 M | 38.5 M | 35.7 M | 35.7 M | 31.6 M | 29.4 M | 29.7 M | 28.7 M | 29.3 M | 27.6 M | 26.8 M | 26.4 M | 23.2 M | 22.1 M | 19.4 M | 20.2 M | 19.4 M | 17.5 M | 15 M | 15.5 M | 15 M | 16.4 M | 13.9 M | 15.4 M | 13.1 M | 10.9 M | 11.6 M | 11.9 M | 13 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
35.5 M | 37.1 M | 34.8 M | 32.2 M | 31.9 M | 28.8 M | 28.4 M | 28.2 M | 26.7 M | 26.5 M | 24.8 M | 23.9 M | 23.7 M | 20.6 M | 19.8 M | 17.2 M | 17.7 M | 17.5 M | 15.8 M | 14.2 M | 13.3 M | 12.9 M | 14.5 M | 12.3 M | 13.6 M | 16.4 M | 10.6 M | 10.2 M | 10.2 M | 11.5 M | 9.46 M | 9.7 M | 9.46 M | 7.89 M | 7.26 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Viemed Healthcare (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Israel
Canada
Britain
China
Costa-rica
